

## Azurin p28 peptide

<b>Cat. No.:</b>	HY-P5910
<b>CAS No.:</b>	897026-25-4
<b>Molecular Formula:</b>	C <sub>122</sub> H <sub>197</sub> N <sub>31</sub> O <sub>47</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	2914.18
<b>Sequence:</b>	Leu-Ser-Thr-Ala-Ala-Asp-Met-Gln-Gly-Val-Val-Thr-Asp-Gly-Met-Ala-Ser-Gly-Leu-Asp-Lys-Asp-Tyr-Leu-Lys-Pro-Asp-Asp
<b>Sequence Shortening:</b>	LSTAADMQGVVTDGMASGLDKDYLPDD
<b>Target:</b>	MDM-2/p53; Apoptosis
<b>Pathway:</b>	Apoptosis
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

#### Description

Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide reduces proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt<sup>[1][2][3]</sup>.

### REFERENCES

- [1]. Jia L, et al. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. *Cancer Chemother Pharmacol*. 2011 Aug;68(2):513-24.
- [2]. Yamada T, et al. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells. *Mol Cancer Ther*. 2009 Oct;8(10):2947-58.
- [3]. Mehta RR, et al. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt. *Angiogenesis*. 2011 Sep;14(3):355-69.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA